European Group for Blood and Marrow Transplantation
- Address
- lock Available on a paid plan
European Group for Blood and Marrow Transplantation
The European Group for Blood and Marrow Transplantation is a leading collaborative network specializing in hematologic malignancies and bone marrow disorders. The organization coordinates multinational clinical research focused on advancing treatment approaches for blood and marrow diseases across Europe.
- Myelodysplastic syndromes (MDS) and anemia management
- Erythropoiesis-stimulating therapies and novel agents
- Red blood cell transfusion dependency interventions
The center is actively involved in Phase 3 comparative effectiveness trials evaluating innovative treatments for myelodysplastic syndromes, particularly in patients with very low, low, or intermediate risk disease requiring red blood cell transfusion support. Research efforts focus on improving outcomes for ESA-naïve patients through rigorous assessment of transfusion independence and hemoglobin response rates with emerging therapeutic agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in European Group for Blood and Marrow Transplantation
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions. | Celgene Corp. | Phase III | Not Recruiting | Dec 2018 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Epoetin Alfa | 1 | Unknown | 2018-12-18 | 2018-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.